Shots:
- Sanofi divulges in its virtual R&D day that the company is anticipating initiation of P-I/II study evaluating the recombinant protein-based vaccine candidate (baculovirus)- developing in collaboration with GSK while expecting the complete approval in H1’20
- Sanofi also highlights capabilities- platforms- and expertise in disease pathways to deliver potentially transformative treatments to patients
- Additionally- Sanofi reveals the clinical status of Venglustat for which P-II/III clinical trial in Gaucher disease type 3 is ongoing- P-III study in Tay-Sachs disease- a type of GM-2 gangliosidoses- was initiated at the beginning of 2020 while P-III study in Fabry diseases to be initiated in 2021
Click here to read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technology
Related News: Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
